Health ProductsDear Healthcare Professional Letter

Calcium Gluconate Injection 10% - Important Information Concerning the Presence of Aluminum - For Health Professionals

· Published by Health Canada · Official notice

Details

Alert type: Dear Healthcare Professional Letter
Category: Drugs
Audience: Healthcare Professionals
Department: Health Canada
Get told about the next health product recall.

We email or text you when Canada issues a recall that matches what you watch: a brand, a product, an allergen. Most never make the news.

Get health product recall alerts

CA$3.99/mo · cancel anytime

Details

This is duplicated text of a letter from Pharmaceutical Partners of Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.

Notice about Health Canada advisories

Health Canada Endorsed Important Safety Information on Calcium Gluconate Injection 10%

July 20, 2011

Dear Health Care Professional,

Subject: Important information concerning the presence of aluminum in Calcium Gluconate Injection 10%

Pharmaceutical Partners of Canada Inc. (PPC), in consultation with Health Canada, would like to inform you that aluminum exposure from parenteral nutrition can be associated with serious central nervous system toxicity, bone and liver damage and anemia in vulnerable populations. Calcium Gluconate Injection contains aluminum and is used in parenteral nutrition.

The presence of aluminum in Calcium Gluconate Injection is thought to come from leaching out of the glass vials. Exposure to more than 4-5 µg/kg/day can be associated with significant central nervous system and bone toxicity. Premature neonates, infants, patients with impaired renal function and patients on parenteral nutrition for prolonged duration are at the highest risk.

  • Aluminum exposure can be associated with significant central nervous system toxicity, bone and liver damage and anaemia. Calcium Gluconate Injection 10% contains aluminum.
  • Premature neonates requiring high doses of calcium gluconate are particularly at risk.
  • Consider the amount of aluminum being administered to susceptible patients and modify therapy as may be necessary.

The vials of PPC's Calcium Gluconate Injection 10% state the maximum amount of aluminum that could be present in the product as no more than 9400 µg/L. This is the maximum amount but the exact level at time of use is unknown as the amount increases over time. Please note that there does not appear to be any significant difference of aluminum levels amongst the various formats (i.e. 10 mL, 50 mL, 100 mL) of this product. The Warning section of the package insert also states: "This product contains aluminum that might be toxic. Aluminum might reach toxic levels with prolonged administration if kidney function is impaired. Premature neonates are particularly at risk because their kidneys are immature, and because they require large amounts of calcium and phosphate solutions which contain aluminum. Research indicates that patients with impaired kidney function, including premature neonates, who receive parenteral levels of aluminum at greater than 4 to 5 µg/kg/day accumulate aluminum at levels associated with central nervous system and bone toxicity."

Healthcare practitioners should consider this information when prescribing calcium gluconate injection for parenteral nutrition in an effort to minimize the exposure to aluminum in vulnerable populations. Alternate therapies and switching to oral administration of calcium as soon as possible should be considered.

To address the issue of aluminum toxicity, PPC is investigating alternate processes and alternate container materials, such as plastic vials, to determine if they will reduce the amount of aluminum present in the product and if they are suitable for utilization. PPC will inform Healthcare Professionals of the date at which the newly manufactured vials are expected to be available.

Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious or unexpected adverse reactions in patients receiving Calcium Gluconate Injection 10% should be reported to Pharmaceutical Partners of Canada Inc. or Health Canada at the following addresses.

Pharmaceutical Partners of Canada Inc.
45 Vogell Road, Suite 200
Richmond Hill, ON, L4B 3P6
Telephone: 905-770-3711
Toll free: 1-877-821-7724

You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following 3 ways:

  • Report online at www.healthcanada.gc.ca/medeffect
  • Call toll-free at 1-866-234-2345
  • Complete a Reporting Form and:
    • Fax toll-free to 1-866-678-6789, or
    • Mail to: Canada Vigilance Program
      Health Canada
      Postal Locator 0701E
      Ottawa, Ontario K1A 0K9

The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.

For other health product inquiries related to this communication, please contact Health Canada at:
Office of Risk Management
E-mail: ORM_BGR_Enquiries@hc-sc.gc.ca
Telephone: 613-954-6493
Fax: 613-954-4474

To change your mailing address or fax number, contact the Market Authorization Holder (Industry).

Please note that this letter will be posted on websites of PPC and Health Canada.

Sincerely,

original signed by

Jim Walker
Vice President Scientific Affairs
Pharmaceutical Partners of Canada Inc.

Get told about the next health product recall.
Get health product recall alerts

CA$3.99/mo · cancel anytime